Quarterly results: Avecho; Melodiol; Bioxyne/BLS; Emyria; Ecofibre; Zelira; Elixinol; AusCann; Botanix by Steve Jones and Martin Lane January 31, 2024July 11, 2024 Avecho Biotechnology will begin its low-dose CBD phase III clinical trial in the next two months […]
Zelira share price rockets as study shows cannabinoid drug outperforms multibillion dollar Pfizer product by Steve Jones June 1, 2023April 30, 2024
Company news: Zelira Therapeutics; Epsilon Healthcare; Creso Pharma by Martin Lane and Steve Jones May 23, 2023April 30, 2024
Company news: Wellnex Life; Creso Pharma; MGC Pharma; Zelira Therapeutics by Martin Lane March 16, 2023April 30, 2024
Company news: Neurotech; Emyria; Cann Group; Incannex; Creso Pharma; Greenfern; Zelira; Organic Genetics by Martin Lane November 24, 2022April 29, 2024
Company news: Zelira Therapeutics; Hygrovest; Epsilon Healthcare by Martin Lane September 22, 2022April 29, 2024
Financial results: Avecho; AusCann; Zelira; Elixinol; Cann Group; Incannex; Creso Pharma; Medlab; Rua Bioscience by Steve Jones and Martin Lane September 1, 2022April 29, 2024
Zelira’s ‘multiple shots on goal’ will drive profitability, says global CEO by Steve Jones June 30, 2022April 29, 2024
Zelira’s Health House acquisition called off by Martin Lane and Steve Jones June 22, 2022April 29, 2024
Company news: Wellnex Life; Incannex; Tetra Bio-Pharma; Zelira by Martin Lane June 8, 2022April 29, 2024
